FdaApplication
BLA 125514
Identifiers
- fda_app_no: BLA125514
Properties
| Property | Value |
|---|---|
| applicant_name | MSD International Business GmbH |
| application_type | BLA |
| approval_date | 2014-09-04 |
Revenue by product
KEYTRUDA
| Period | Revenue |
|---|---|
| Q2 2026 | $7.9B |
| Q1 2026 | $7.9B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.1B |
| Q2 2025 | $8.0B |
| Q1 2025 | $7.2B |
| Q4 2024 | $7.8B |
| Q3 2024 | $7.4B |
| Q2 2024 | $7.3B |
| Q1 2024 | $6.9B |
| Q4 2023 | $6.6B |
| Q3 2023 | $6.3B |
| Q2 2023 | $6.3B |
| Q1 2023 | $5.8B |
| Q4 2022 | $5.5B |
| Q3 2022 | $5.4B |
| Q2 2022 | $5.3B |
| Q1 2022 | $4.8B |
| Q4 2021 | $4.6B |
| Q3 2021 | $4.5B |
| Q2 2021 | $4.2B |
| Q1 2021 | $3.9B |
| Q4 2020 | $4.0B |
| Q3 2020 | $3.7B |
| Q2 2020 | $3.4B |
| Q1 2020 | $3.3B |
| Q4 2019 | $3.1B |
| Q3 2019 | $3.1B |
| Q2 2019 | $2.6B |
| Q1 2019 | $2.3B |
| Q4 2018 | $2.2B |
| Q3 2018 | $1.9B |
| Q2 2018 | $1.7B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
KEYTRUDA
| Period | Revenue |
|---|---|
| Q2 2026 | $7.9B |
| Q1 2026 | $7.9B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.1B |
| Q2 2025 | $8.0B |
| Q1 2025 | $7.2B |
| Q4 2024 | $7.8B |
| Q3 2024 | $7.4B |
| Q2 2024 | $7.3B |
| Q1 2024 | $6.9B |
| Q4 2023 | $6.6B |
| Q3 2023 | $6.3B |
| Q2 2023 | $6.3B |
| Q1 2023 | $5.8B |
| Q4 2022 | $5.5B |
| Q3 2022 | $5.4B |
| Q2 2022 | $5.3B |
| Q1 2022 | $4.8B |
| Q4 2021 | $4.6B |
| Q3 2021 | $4.5B |
| Q2 2021 | $4.2B |
| Q1 2021 | $3.9B |
| Q4 2020 | $4.0B |
| Q3 2020 | $3.7B |
| Q2 2020 | $3.4B |
| Q1 2020 | $3.3B |
| Q4 2019 | $3.1B |
| Q3 2019 | $3.1B |
| Q2 2019 | $2.6B |
| Q1 2019 | $2.3B |
| Q4 2018 | $2.2B |
| Q3 2018 | $1.9B |
| Q2 2018 | $1.7B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| KEYTRUDA | PEMBROLIZUMAB | 50MG | For Injection |
| KEYTRUDA | — | 100MG/4ML (25MG/ML) | Injection |
2 products